Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The mammalian target of rapamycin (mTOR)/p70 S6 kinase 1 (S6K1) pathway is a critical signaling component in the development of obesity-linked insulin resistance and operates a nutrient-sensing negative feedback loop toward the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathway. Whereas acute treatment of insulin target cells with the mTOR complex 1 (mTORC1) inhibitor rapamycin prevents nutrient-induced insulin resistance, the chronic effect of rapamycin on insulin sensitivity and glucose metabolism in vivo remains elusive. RESEARCH DESIGN AND METHODS: To assess the metabolic effects of chronic inhibition of the mTORC1/S6K1 pathway, rats were treated with rapamycin (2 mg/kg/day) or vehicle for 15 days before metabolic phenotyping. RESULTS: Chronic rapamycin treatment reduced adiposity and fat cell number, which was associated with a coordinated downregulation of genes involved in both lipid uptake and output. Rapamycin treatment also promoted insulin resistance, severe glucose intolerance, and increased gluconeogenesis. The latter was associated with elevated expression of hepatic gluconeogenic master genes, PEPCK and G6Pase, and increased expression of the transcriptional coactivator peroxisome proliferator–activated receptor-γ coactivator-1α (PGC-1α) as well as enhanced nuclear recruitment of FoxO1, CRTC2, and CREB. These changes were observed despite normal activation of the insulin receptor substrate/PI 3-kinase/Akt axis in liver of rapamycin-treated rats, as expected from the blockade of the mTORC1/S6K1 negative feedback loop. CONCLUSIONS: These findings unravel a novel mechanism by which mTORC1/S6K1 controls gluconeogenesis through modulation of several key transcriptional factors. The robust induction of the gluconeogenic program in liver of rapamycin-treated rats underlies the development of severe glucose intolerance even in the face of preserved hepatic insulin signaling to Akt and despite a modest reduction in adiposity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Specifically, compensatory pathways are activated in response to chronic rapamycin treatment [66, 67].”
From AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma (2021) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 3×
“Diabetes 59:1338–1348, 2010 The mammalian target of rapamycin (mTOR) is a Ser/Thr kinase that belongs to the phosphatidylinositol (PI) kinase-related protein kinase family (1).”
BackgroundWatterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K., et al. (2001) · Nature · doi:10.1038/35093050 · Cited by 1,821 · cited 1×
“We also found that rapamycin markedly increases PGC-1 mRNA expression, which likely contributes to the upregulation of the gluconeogenic enzymes, as observed in type 2 diabetes (32).”
BackgroundAbsence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex
Cunningham, J. T., Rodgers, J. T., Arlow, D. H., Vazquez, F., Mootha, V. K., & Puigserver, P. (2007) · Nature · doi:10.1038/nature06322 · Cited by 1,488
Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., et al. (2003) · Nature · doi:10.1038/nature01667 · Cited by 1,487
CREB regulates hepatic gluconeogenesis through the coactivator PGC-1
Herzig, S., Long, F., Jhala, U. S., Hedrick, S., Quinn, R., Bauer, A., Rudolph, D., Schutz, G., Yoon, C., Puigserver, P., et al. (2001) · Nature · doi:10.1038/35093131 · Cited by 1,440 · cited 1×
“CREB may also promote gluconeogenesis through increased PGC-1 expression (43).”
BackgroundGuertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,415 · cited 1×
“GSK-3 phosphorylation was recently found to be preserved despite complete loss of Akt Ser473 phosphorylation in mouse embryo fibroblasts from rictor knockout animals (49).”
BackgroundPeterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202 · cited 1×
“The mTOR complex 1 (mTORC1) is composed of mTOR, G L, PRAS40, deptor, and raptor and regulates cell growth, whereas the complex 2 (mTORC2) consists of mTOR, G L, protor-1, mSIN1, deptor, and rictor and controls cytoskeleton regulation and cell survival (1,2).”
Background
Research works printed but not linked: 1
- Hamada, Upregulation of the mTOR complex 1 pathway by Rheb in pancreatic β cells leads to increased β cell mass and prevention of hyperglycemia, Diabetes
Cited by
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
“Rapamycin reduces adipose tissue size and b-cell mass and function and causes hyperlipidemia, severe insulin resistance, and glucose intolerance and promotes hepatic gluconeogenesis (Aggarwal et al., 2006; Cunningham et al., 2007; Fraenkel et al., 2008; Houde et al., 2010) (Figure 5A).”
Rapamycin: one drug, many effects
Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
Henske, E. P., Jóźwiak, S., Kingswood, J. C., Sampson, J. R., & Thiele, E. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.35 · Cited by 831
Miller, R. A., Harrison, D. E., Astle, C. M., Fernandez, E., Flurkey, K., Han, M., Javors, M. A., Li, X., Nadon, N. L., Nelson, J. F., et al. (2014) · Aging Cell · doi:10.1111/acel.12194 · Cited by 621
“Chronic injection of rapamycin also causes hepatic insulin resistance in young C57BL/6 mice and SpragueDawley rats (Houde et al., 2010; Lamming et al., 2012).”
BackgroundmTOR complex 2 signaling and functions
Oh, W. J., & Jacinto, E. (2011) · Cell Cycle · doi:10.4161/cc.10.14.16586 · Cited by 562
Essential role for autophagy in life span extension
Madeo, F., Zimmermann, A., Maiuri, M. C., & Kroemer, G. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73946 · Cited by 464
“60–64) yet provokes severe side effects such as insulin resistance (65), glucose intolerance (66), testicular degeneration, and cataracts (63).”
mTOR in aging, metabolism, and cancer
Cornu, M., Albert, V., & Hall, M. N. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.12.005 · Cited by 449
The SIRT1 Activator SRT1720 Extends Lifespan and Improves Health of Mice Fed a Standard Diet
Mitchell, S. J., Martin-Montalvo, A., Mercken, E. M., Palacios, H. H., Ward, T. M., Abulwerdi, G., Minor, R. K., Vlasuk, G. P., Ellis, J. L., Sinclair, D. A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.01.031 · Cited by 398
“However, chronic administration of rapamycin induces glucose intolerance, insulin resistance and incidence of diabetogenic effects (Deblon et al., 2012; Houde et al., 2010; Lamming et al., 2012) despite lifespan extension in mice (Harrison et al.”
BackgroundRapamycin extends murine lifespan but has limited effects on aging
Neff, F., Flores-Dominguez, D., Ryan, D. P., Horsch, M., Schröder, S., Adler, T., Afonso, L. C., Aguilar-Pimentel, J. A., Becker, L., Garrett, L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67674 · Cited by 374
“Although we were unable to detect any effect of rapamycin on fat mass in young mice (Supplemental Figure 10), previously documented direct effects of rapamycin on fat mass and adipogenesis (30, 31) caution against the conclusion that rapamycin’s effects were aging dependent.”
Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases
Perl, A. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.172 · Cited by 332
mTOR couples cellular nutrient sensing to organismal metabolic homeostasis
Howell, J. J., & Manning, B. D. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.12.003 · Cited by 331
Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes
Shivaswamy, V., Boerner, B., & Larsen, J. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1084 · Cited by 328
Strategies for the management of adverse events associated with mTOR inhibitors
Kaplan, B., Qazi, Y., & Wellen, J. R. (2014) · Transplantation Reviews · doi:10.1016/j.trre.2014.03.002 · Cited by 322
“mTOR and its downstream target S6 kinase 1 (S6K1) interact with various growth factors, hormones, and nutrients to regulate protein translation and cell growth, proliferation, and survival [5,62].”
BackgroundInfluentialThe Roles of mTOR Complexes in Lipid Metabolism
Caron, A., Richard, D., & Laplante, M. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034355 · Cited by 314
Role of mTOR in Glucose and Lipid Metabolism
Mao, Z., & Zhang, W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072043 · Cited by 296
mTOR signaling in cellular and organismal energetics
Albert, V., & Hall, M. N. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.12.001 · Cited by 304
The role of mammalian target of rapamycin (mTOR) in insulin signaling
Yoon, M.-S. (2017) · Nutrients · doi:10.3390/nu9111176 · Cited by 300
“β-cell mass is reduced in chronic rapamycin-treated rats [114].”
BackgroundEtiology of Metabolic Syndrome and Dietary Intervention
Xu, H., Li, X., Adams, H., Kubena, K., & Guo, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010128 · Cited by 257
“of gluconeogenic genes and a rise in very-low-density lipoprotein (VLDL) secretion [15,31].”
BackgroundRapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island
Arriola Apelo, S. I., & Lamming, D. W. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw090 · Cited by 239
Perl, A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12756 · Cited by 218
Rapamycin for longevity: opinion article
Blagosklonny, M. V. (2019) · Aging · doi:10.18632/aging.102355 · Cited by 205
“However, in some (but not all) rodent models, chronic treatment with rapamycin can also cause glucose intolerance and even insulin resistance [53-56].”
BackgroundmTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells
Ardestani, A., Lupse, B., Kido, Y., Leibowitz, G., & Maedler, K. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.004 · Cited by 190
“…2001; Tzatsos and Kandror, 2006), prolonged treatment exacerbates diabetes (Cunningham et al., 2007; Deblon et al., 2012; Fraenkel et al., 2008; Houde et al., 2010; Lamming et al., 2012; Shum et al., 2016; Veilleux et al., 2010) and reduces life span of diabetic mice (Sataranatarajan et al.,…”
BackgroundActivation of mTORC1 is essential for β-adrenergic stimulation of adipose browning
Liu, D., Bordicchia, M., Zhang, C., Fang, H., Wei, W., Li, J.-L., Guilherme, A., Guntur, K., Czech, M. P., & Collins, S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83532 · Cited by 193
Duration of Rapamycin Treatment Has Differential Effects on Metabolism in Mice
Fang, Y., Westbrook, R., Hill, C., Boparai, R. K., Arum, O., Spong, A., Wang, F., Javors, M. A., Chen, J., Sun, L. Y., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.02.008 · Cited by 195
“In various studies, the length of rapamycin treatment ranged from 2 (Houde et al., 2010; Fraenkel et al., 2008) or 6 weeks (Chen et al., 2009; Chang et al., 2009) to 1.5– 2 years (Harrison et al., 2009; Anisimov et al., 2011), when rapamycin led to longer survivorship.”
InfluentialBarlow, A. D., Nicholson, M. L., & Herbert, T. P. (2013) · Diabetes · doi:10.2337/db13-0106 · Cited by 191
Audet-walsh, É., & Giguére, V. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.121 · Cited by 176
Arriola Apelo, S. I., Neuman, J. C., Baar, E. L., Syed, F. A., Cummings, N. E., Brar, H. K., Pumper, C. P., Kimple, M. E., & Lamming, D. W. (2016) · Aging Cell · doi:10.1111/acel.12405 · Cited by 182
“One treatment cycle later, we performed a pyruvate tolerance test (PTT); pyruvate can be utilized as a substrate for gluconeogenesis by the liver, permitting us to assess hepatic gluconeogenesis (Houde et al., 2010; Lamming et al., 2012).”
MethodSchreiber, K. H., Ortiz, D., Academia, E. C., Anies, A. C., Liao, C., & Kennedy, B. K. (2015) · Aging Cell · doi:10.1111/acel.12313 · Cited by 177
“…it will likely be beneficial to inhibit both mTORC1 and mTORC2 where others, such as the aging process in general, might benefit from mTORC1-selective inhibition to avoid the negative metabolic side effects associated with prolonged treatment of the drug (Stallone et al., 2009; Houde et al., 2010).”
BackgroundInfluentialPajvani, U. B., Qiang, L., Kangsamaksin, T., Kitajewski, J., Ginsberg, H. N., & Accili, D. (2013) · Nature Medicine · doi:10.1038/nm.3259 · Cited by 168
Calorie restriction mimetics: Can you have your cake and eat it, too?
Ingram, D. K., & Roth, G. S. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2014.11.005 · Cited by 161
Zhao, D., Yang, J., & Yang, L. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/6437467 · Cited by 161
“However, more than six weeks treatment could improve insulin sensitivity [124].”
BackgroundThe central moTOR of metabolism
Simcox, J., & Lamming, D. W. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.02.024 · Cited by 174
A comparative perspective on lipid storage in animals
Birsoy, K., Festuccia, W. T., & Laplante, M. (2013) · Journal of Cell Science · doi:10.1242/jcs.104992 · Cited by 179
Self-citationChronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats
Deblon, N., Bourgoin, L., Veyrat‐Durebex, C., Peyrou, M., Vinciguerra, M., Caillon, A., Maeder, C., Fournier, M., Montet, X., Rohner‐Jeanrenaud, F., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01716.x · Cited by 172
“Hyperlipidaemia, potentially resulting from increased adipose tissue lipolysis or hepatic TG synthesis, has been suggested to represent one of the factors contributing to peripheral insulin resistance following systemic mTOR inhibition (Morrisett et al., 2002; Chakrabarti et al., 2010; Houde et al., 2010; Kumar et al.…”
BackgroundResultInfluentialChaveroux, C., Eichner, L. J., Dufour, C. R., Shatnawi, A. A., Khoutorsky, A., Bourque, G., Sonenberg, N., & Giguère, V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.003 · Cited by 172
“Side effects of these drugs have been reported such as hyperlipidemia and hypercholesterolemia and activation of gluconeogenesis in liver, a major organ for lipid biosynthesis (Houde et al., 2010; Levy et al., 2006; Morrisett et al., 2002).”
BackgroundNguyen, L. S., Vautier, M., Allenbach, Y., Zahr, N., Benvéniste, O., Funck‐Brentano, C., & Salem, J. (2019) · Drug Safety · doi:10.1007/s40264-019-00810-9 · Cited by 173
Testa, G., Biasi, F., Poli, G., & Chiarpotto, E. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660699 · Cited by 163
“[518] Houde VP, Brûlé S, Festuccia WT, et al.”
BackgroundRecent Advances in Adipose mTOR Signaling and Function: Therapeutic Prospects
Cai, H., Dong, L., & Liu, F. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.11.011 · Cited by 162
“While hyperactivation of the mTORC1 signaling pathway in obese mice and humans appears to have a role in developing insulin resistance and diabetes, inhibition of the mTOR pathway by rapamycin has been demonstrated to have both beneficial and detrimental effects on insulin sensitivity and whole-body metabolism [101,10…”
Sadria, M., & Layton, A. T. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00706-1 · Cited by 154
“(19) The loss of insulin sensitivity is due to the reduction of AKT_T308_S473, which plays a pivotal role in the translocation of GLUT4.(14, 15) Sebastian and co-workers demonstrated intermittent administration of rapamycin (e.”
BackgroundAnti-aging pharmacology: Promises and pitfalls
Vaiserman, A. M., Lushchak, O. V., & Koliada, A. K. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.08.004 · Cited by 151
“Side effects of chronic rapamycin dministration such as hyperglycemia, glucose intolerance and nsulin resistance, have been revealed in some rodent studies Deblon et al., 2012; Houde et al., 2010).”
BackgroundCaloric restriction and cancer: molecular mechanisms and clinical implications
Meynet, O., & Ricci, J. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.05.001 · Cited by 150
Amino Acid Sensing in Metabolic Homeostasis and Health
Hu, X., & Guo, F. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa026 · Cited by 149
Sirolimus Therapy in Infants with Severe Hyperinsulinemic Hypoglycemia
Senniappan, S., Alexandrescu, S., Tatevian, N., Shah, P., Arya, V. B., Flanagan, S. E., Ellard, S., Rampling, D., Ashworth, M. T., Brown, R. E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310967 · Cited by 142
mTOR: A Cellular Regulator Interface in Health and Disease
Boutouja, F., Stiehm, C. M., & Platta, H. W. (2019) · Cells · doi:10.3390/cells8010018 · Cited by 150
“While short-term inhibition of TORC1 by rapamycin causes TORC2-mediated insulin resistance [13,158], the long-term blockade of TORC1 was reported to reduce high-fat diet-induced obesity in mice [159,160].”
BackgroundIntermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice
Apelo, S. I. A., Pumper, C. P., Baar, E. L., Richardson, N. E., & Lamming, D. W. (2016) · The Journals of Gerontology Series A · doi:10.1093/gerona/glw064 · Cited by 138
“In contrast to many rapamycin studies that have observed decreased food intake (30), we observed a trend toward increased food intake.”
ResultBlanchard, P.-G., Festuccia, W. T., Houde, V. P., St‐Pierre, P., Brûlé, S., Turcotte, V., Côté, M., Bellmann, K., Marette, A., & Deshaies, Y. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m021485 · Cited by 139
Self-citationTargeting PI3K-AKT/mTOR signaling in the prevention of autism
Sharma, A., & Mehan, S. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105067 · Cited by 140
Liu, M., Bai, J., He, S., Villarreal, R., Hu, D., Zhang, C., Yang, X., Liang, H., Slaga, T. J., Yu, Y., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.03.018 · Cited by 133
“S5C and S5D), which has been suggested to be the result of increased gluconeogenesis in the liver (Houde et al., 2010; Lamming et al., 2012).”
Patsenker, E., Schneider, V., Ledermann, M., Saegesser, H., Dorn, C., Hellerbrand, C., & Stickel, F. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.10.044 · Cited by 123
“Journal of Hepatology 201 Experimental data from rodent studies show conflicting results with either dose-dependent steatogenesis of rapamycin in rodents [1,23] or even a reduction of liver fat [9,10].”
Depletion of Rictor, an essential protein component of m TORC 2, decreases male lifespan
Lamming, D. W., Mihaylova, M. M., Katajisto, P., Baar, E. L., Yilmaz, O. H., Hutchins, A., Gultekin, Y., Gaither, R., & Sabatini, D. M. (2014) · Aging Cell · doi:10.1111/acel.12256 · Cited by 111
“Long-term rapamycin treatment results in glucose intolerance in humans, rats, and C57BL/6 mice as well as genetically heterogeneous HET3 mice (Houde et al., 2010; Gyurus et al., 2011; McCormack et al., 2011; Lamming et al., 2013).”
BackgroundVergès, B. L., & Cariou, B. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.09.014 · Cited by 131
The Role of the PI3K Signaling Pathway in CD4+ T Cell Differentiation and Function
Han, J. M., Patterson, S. J., & Levings, M. K. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00245 · Cited by 137
“Moreover, rapamycin has many deleterious side effects such as inhibition of islet survival and function (Tanemura et al., 2012), and induction of glucose intolerance and hyperlipidemia (Morrisett et al., 2002; Houde et al., 2010).”
BackgroundSeparation of the gluconeogenic and mitochondrial functions of PGC-1α through S6 kinase
Lustig, Y., Ruas, J. L., Estall, J. L., Lo, J. C., Devarakonda, S., Laznik, D., Choi, J. H., Ono, H., Olsen, J. V., & Spiegelman, B. M. (2011) · Genes & Development · doi:10.1101/gad.2054711 · Cited by 128
“Chronic rapamycin treatment in rats was shown to cause insulin resistance and glucose intolerance, in part through inducing the expression of the gluconeogenic enzymes PEPCK and G6Pase and PGC-1a (Houde et al. 2010).”
BackgroundA Self-Assembled α-Synuclein Nanoscavenger for Parkinson’s Disease
Liu, J., Liu, C., Zhang, J., Zhang, Y., Liu, K., Song, J., Sreenivasmurthy, S. G., Wang, Z., Shi, Y., Chu, C., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b06453 · Cited by 120
Blagosklonny, M. V. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.506 · Cited by 123
Towards natural mimetics of metformin and rapamycin
Aliper, A. M., Jellen, L. C., Cortese, F., Artemov, A. V., Karpinsky‐Semper, D., Moskalev, A., Swick, A. G., & Zhavoronkov, A. A. (2017) · Aging · doi:10.18632/aging.101319 · Cited by 115
“In addition, chronic rapamycin use can lead to hepatic gluconeogenesis, insulin resistance, and severe glucose intolerance in rats [78], impaired glucose tolerance in mice [79], and even diabetes in male mice [80].”
BackgroundThe Sam68 STAR RNA-Binding Protein Regulates mTOR Alternative Splicing during Adipogenesis
Huot, M., Vogel, G., Zabarauskas, A., Ngo, C. T.-A., Coulombe‐Huntington, J., Majewski, J., & Richard, S. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.02.007 · Cited by 115
Potential therapeutic effects of mTOR inhibition in atherosclerosis
Kurdi, A., Meyer, G. R. Y. D., & Martinet, W. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12820 · Cited by 113
Distinct and additive effects of calorie restriction and rapamycin in aging skeletal muscle
Ham, D. J., Börsch, A., Chojnowska, K., Lin, S., Leuchtmann, A. B., Ham, A. S., Thürkauf, M., Delezie, J., Furrer, R., Bürri, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29714-6 · Cited by 122
Yang, S., Lee, H. Y., Young, D. M., Tien, A., Rowson-Baldwin, A., Shu, Y., Jan, Y. N., & Jan, L. Y. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0834-3 · Cited by 116
Tuberous sclerosis: a review of the past, present, and future
Uysal, S. P., & Şahin, M. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2002-133 · Cited by 119
Blättler, S. M., Cunningham, J. T., Verdeguer, F., Chim, H., Haas, W., Liu, H., Romanino, K., Rüegg, M. A., Gygi, S. P., Shi, Y., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.008 · Cited by 116
“For example, the liver would contribute through hepatic insulin resistance to uncontrolled higher rates of hepatic glucose production, as shown using hyperinsulinemic-euglycemic clamps in Figure S1E and as previously suggested in rats (Houde et al., 2010).”
BackgroundResultLee, L., Ito, T., & Jensen, R. T. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1476492 · Cited by 109
“Inhibition of mTOR pathway was reported to attenuate insulin secretion in an insulinoma cell line [120].”
BackgroundMazucanti, C. H., Cabral‐Costa, J. V., Vasconcelos, A. R., Andreotti, D. Z., Scavone, C., & Kawamoto, E. M. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150610125715 · Cited by 112
“However, some data suggests rapamycin to have unwanted, mainly metabolic, effects in rodents, including insulin resistance, hyperlipidemia, glucose intolerance and hypophosphatemia [46-49].”
BackgroundMolecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors
Zhang, Y., Yan, H., Xu, Z., Yang, B., Luo, P., & He, Q. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1663169 · Cited by 109
“found that mice with chronic rapamycin treatment had impaired lipid deposition in adipose tissue, likely resulting in elevated plasma triglyceride and nonesterified fatty acid levels [29].”
BackgroundVergès, B. L., Walter, T., & Cariou, B. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0586 · Cited by 101
Jiang, Y. Z., Rose, A. J., Sijmonsma, T., Bröer, A., Pfenninger, A., Herzig, S., Schmoll, D., & Bröer, S. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.02.003 · Cited by 102
Low-dose rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome
Siegmund, S. E., Yang, H., Sharma, R., Javors, M., Skinner, O., Mootha, V., Hirano, M., & Schon, E. A. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx341 · Cited by 92
Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to
Blagosklonny, M. V. (2012) · Aging · doi:10.18632/aging.100461 · Cited by 95
“As described by Lamming et al [1, 2] extending several previous observations [3-6], chronic administration of high doses of rapamycin causes insulin resistance in mice.”
BackgroundA triple drug combination targeting components of the nutrient-sensing network maximizes longevity
Castillo-Quan, J. I., Tain, L. S., Kinghorn, K. J., Li, L., Grönke, S., Hinze, Y., Blackwell, T. K., Bjedov, I., & Partridge, L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913212116 · Cited by 92
“Rapamycin treatment results in insulin resistance and dyslipidemia in patients and mice (4, 18, 22), and this disturbance manifests as hypertriglyceridemia in Drosophila (5).”
BackgroundŚlusarz, A., & Pulakat, L. (2015) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000246 · Cited by 98
Acute mTOR inhibition induces insulin resistance and alters substrate utilization in vivo
Kleinert, M., Sylow, L., Fazakerley, D. J., Krycer, J. R., Thomas, K. C., Oxboll, A., Jordy, A. B., Jensen, T. E., Yang, G., Schjerling, P., et al. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.06.004 · Cited by 93
“Keywords Skeletal muscle; Metabolism; Glucose uptake; mTORC2; Rictor; Glycolysis”
BackgroundZhou, W. P., & Ye, S. (2018) · Cell Biology International · doi:10.1002/cbin.11015 · Cited by 90
Metabolic consequences of modern immunosuppressive agents in solid organ transplantation
Bamgbola, O. (2016) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018816641580 · Cited by 85
“Consequently, the reduction in the capacity of adipose tissue clearance of fat results in hyperlipidemia [Houde et al. 2010].”
BackgroundYe, L., Varamini, B., Lamming, D. W., Sabatini, D. M., & Baur, J. A. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00177 · Cited by 93
“Surprisingly, rapamycin causes insulin resistance (Houde et al., 2010; Lamming et al., 2012) and inhibits both the production and function of mitochondria, at least in cells (Schieke et al.”
BackgroundResultThe mixed blessing of AMPK signaling in Cancer treatments
Sadria, M., Seo, D., & Layton, A. T. (2022) · BMC Cancer · doi:10.1186/s12885-022-09211-1 · Cited by 87
“Furthermore, excessive inhibition of mTORC2 may overly suppress AKT, which is essential in the translocation of GLUT4, and lead to insulin insensitivity (45).”
BackgroundShindyapina, A. V., Cho, Y., Kaya, A., Tyshkovskiy, A., Castro, J. P., Deik, A., Gordevičius, J., Poganik, J. R., Clish, C. B., Horvath, S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo5482 · Cited by 96
“To test whether EL rapamycin might cause hyperlipidemia similarly to the acute rapamycin treatment (29), we performed lipidomics analyses of the liver and serum of 20- to 22-month-old male and female rapamycin groups.”
MethodRapamycin Blocks Induction of the Thermogenic Program in White Adipose Tissue
Tran, C. M., Mukherjee, S., Ye, L., Frederick, D. W., Kissig, M., Davis, J. G., Lamming, D. W., Seale, P., & Baur, J. A. (2016) · Diabetes · doi:10.2337/db15-0502 · Cited by 86
“Rodents treated with rapamycin develop insulin resistance, glucose intolerance, and hyperlipidemia, often associated with changes in adiposity (2,3).”
BackgroundMetabolic Communication and Healthy Aging: Where Should We Focus Our Energy?
Smith, H. J., Sharma, A., & Mair, W. B. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.06.011 · Cited by 87
Metabolic syndrome: Is immunosuppression to blame?
Watt, K. D. S. (2011) · Liver Transplantation · doi:10.1002/lt.22386 · Cited by 87
“The acute inhibition of mTOR by sirolimus has been shown to prevent the insulin-resistant effects of excess nutrients,(28) but the chronic inhibition of mTOR promotes insulin resistance and severe glucose intolerance.(27) This has largely been attributed to reduced b cell mass (which does not clearly affect b cell fun…”
BackgroundInfluentialThe PI3K/Akt/mTOR pathway regulates the replicative senescence of human VSMCs
Tan, P., Wang, Y., Li, S., Wang, Y., He, J., Chen, Y., Deng, H., Huang, W., Zhan, J., & Liu, Y. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2796-9 · Cited by 83
“Drugs that can inhibit the aging of VSMCs have been revealed to delay vascular aging and to be potential treatments for cardiovascular diseases [22].”
BackgroundPacker, M. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa360 · Cited by 85
Pereira, M. J., Palming, J., Rizell, M., Aureliano, M., Carvalho, E., Svensson, M. K. E., & Eriksson, J. W. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.10.030 · Cited by 87
“In contrast, others have shown that rapamycin reduces LPL gene expression and activity in the retroperitoneal adipose tissue of rats treated with the drug (Blanchard et al., 2012; Houde et al., 2010).”
BackgroundResultRegulation of Cardiac Expression of the Diabetic Marker MicroRNA miR-29
Arnold, N., Koppula, P. R., Gul, R., Luck, C., & Pulakat, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103284 · Cited by 79
Macia, M. G., Santos‐Ledo, A., Leslie, J., Paish, H. L., Collins, A., Scott, R., Watson, A. A., Burgoyne, R. A., White, S. A., French, J., et al. (2021) · Hepatology · doi:10.1002/hep.32048 · Cited by 81
Fasting and rapamycin: diabetes versus benevolent glucose intolerance
Blagosklonny, M. V. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1822-8 · Cited by 74
Tuberous Sclerosis Complex-1 Deficiency Attenuates Diet-Induced Hepatic Lipid Accumulation
Kenerson, H. L., Yeh, M. M., & Yeung, R. S. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018075 · Cited by 74
“These findings are consistent with previous reports of glucose intolerance following chronic rapamycin treatment [34] [35].”
ResultGH and ageing: Pitfalls and new insights
Bartke, A., & Darcy, J. (2017) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2017.02.005 · Cited by 78
The role of the TOR pathway in mediating the link between nutrition and longevity
Lushchak, O., Strilbytska, O., Piskovatska, V., Storey, K. B., Koliada, A., & Vaiserman, A. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.03.005 · Cited by 73
Lamming, D. W., Ye, L., Astle, C. M., Baur, J. A., Sabatini, D. M., & Harrison, D. E. (2013) · Aging Cell · doi:10.1111/acel.12097 · Cited by 74
“Surprisingly, and in contrast to these results, we found that dietary rapamycin did not induce insulin resistance in HET3 mice as measured by ITT in either young (Fig.”
InfluentialJoshi, S. K., Liu, X., Samagh, S. P., Lovett, D. H., Bodine, S. C., Kim, H. T., & Feeley, B. T. (2012) · Journal of Orthopaedic Research® · doi:10.1002/jor.22254 · Cited by 73
Metabolic Consequences of Solid Organ Transplantation
Bhat, M., Usmani, S. E., Azhie, A., & Woo, M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa030 · Cited by 80
Biase, S. D., Shim, H. S., Kim, K. H., Vinciguerra, M., Rappa, F., Wei, M., Brandhorst, S., Cappello, F., Mirzaei, H., Lee, C. D., et al. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2001951 · Cited by 79
The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 Diabetes Mellitus
Suhara, T., Baba, Y., Shimada, B. K., Higa, J. K., & Matsui, T. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0865-4 · Cited by 72
Modulation of mTOR Signaling in Cardiovascular Disease to Target Acute and Chronic Inflammation
Kaldirim, M., Lang, A., Pfeiler, S., Fiegenbaum, P., Kelm, M., Bönner, F., & Gerdes, N. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.907348 · Cited by 73
“Treatment of atherosclerosis would supposedly necessitate a longterm mTOR inhibition, that causes hyperglycemia itself and could deteriorate the deranged metabolism of diabetic patients (148).”
BackgroundTargeting glucose metabolism for healthy aging
Brewer, R. A., Gibbs, V. K., & Smith, D. L. (2016) · Nutrition and Healthy Aging · doi:10.3233/nha-160007 · Cited by 73
“These less common exceptions where longevity extension is uncoupled from improved glucose metabolism include cases where the insulin signaling pathway in the brain is disrupted resulting in increased longevity (relative to within study controls) despite mild glucose intolerance, or where downstream…”
BackgroundLiang, H., Habte‐Tsion, H., Ge, X., Ren, M., Xie, J., Miao, L., Zhou, Q., Lin, Y., & Pan, W. (2017) · Scientific Reports · doi:10.1038/s41598-017-06104-3 · Cited by 70
Rapamycin-induced metabolic defects are reversible in both lean and obese mice
Liu, Y., Diaz, V., Fernandez, E., Strong, R., Ye, L., Baur, J. A., Lamming, D. W., Richardson, A., & Salmon, A. B. (2014) · Aging · doi:10.18632/aging.100688 · Cited by 68
“also found that 15 days of rapamycin treatment caused similar metabolic impairments in Sprague-Dawley rats [19].”
BackgroundResultInfluentialmTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand?
Kezić, A., Popović, L., & Lalic, K. S. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/2640342 · Cited by 71
“Despite the improved insulin signaling in the liver of rapamycintreated rats, which came out from the blockade of the mTOR/S6K1 negative feedback loop, the induction of gluconeogenic pathway in the liver potentiates glucose intolerance [59, 60].”
Background
Metadata
- Authors
- Houde, V. P., Brûlé, S., Festuccia, W. T., Blanchard, P.-G., Bellmann, K., Deshaies, Y., & Marette, A.
- Affiliations
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Corresponding author
- Marette, André
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-03-18
- Volume
- 59
- Issue
- 6
- Pages
- 1338-1348
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2874694
- OpenAlex
- W2153442288
- Cited by
- 456
- References
- 51
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 14 · 2023: 25 · 2022: 20 · 2021: 30 · 2020: 25 · 2019: 26 · 2018: 33 · 2017: 37 · 2016: 35 · 2015: 42 · 2014: 47 · 2013: 32 · 2012: 30
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval
- Canadian Institutes of Health Research (144336)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- hepatic gluconeogenesis, impaired glucose tolerance, hyperlipidemia, insulin resistance, PGC-1α, FOXO1, CRTC2, CREB, PI3K/Akt signaling, phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, adiposity
- MeSH terms
- Adipose Tissue, Animals, Blood Glucose, C-Peptide, Fatty Acids, Nonesterified, Glucagon, Hyperlipidemias, Immunosuppressive Agents, Insulin, Liver, Male, Pyruvates, RNA, Triglycerides, Down-Regulation, Polymerase Chain Reaction, Rats, Sprague-Dawley, Adipocytes, Glucose Intolerance, Muscle, Skeletal, Sirolimus, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.